Product Description
Epitinib could cross BBB and show its efficacy in brain metastasis tumors. For Treating Patients With Glioblastoma (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03231501)
Mechanisms of Action: EGFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: HUTCHMED
Company Location: Asia Pacific
Company Founding Year: 2000
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified|Glioblastoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20170170 |
CTR20170170 | N/A |
Unknown |
Glioblastoma |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
|
NCT03231501 |
2016-813-00CH3 | P1 |
Unknown status |
Glioblastoma |
2020-06-30 |
88% |
2022-06-03 |
Primary Endpoints|Treatments|Trial Status |
NCT02590952 |
2010-813-00CH1 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2019-04-30 |
12% |
2020-02-18 |
|
CTR20130972 |
CTR20130972 | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|